For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and the formulated version represents a true advancement . These groundbreaking therapies protect the transthyretin protein, slowing its destructive build-up and lessening th